GlassScriptPhysician profile
Preston Eddie Bishop
NPI 1801866181
$8,207.17
in general payments reported to CMS, 2019-2025
37 companies · $1,272 in 2025
The $1,272 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,146 · 2020: $1,012 · 2021: $1,188 · 2022: $1,240 · 2023: $1,206 · 2024: $1,143 · 2025: $1,272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,552 · Education: $68.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,552.03 |
| Education | $68.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $951.11 | 2019-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $929.43 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $760.91 | 2019-2025 | |
| Abbvie INC. | $696.86 | 2021-2025 | Vraylar, Linzess, Qulipta |
| Lilly USA, LLC | $680.32 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $618.23 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Astellas Pharma US INC | $403.70 | 2019-2025 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $380.98 | 2020-2022 | |
| Glaxosmithkline, LLC. | $375.59 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Dexcom, INC. | $302.48 | 2021-2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $289.18 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $237.25 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $211.04 | 2019-2023 | |
| Kowa Pharmaceuticals America, INC. | $200.66 | 2020-2025 | Zoryve |
| Merck Sharp & Dohme LLC | $173.37 | 2019-2025 | Gardasil 9, Lagevrio, Gardasil |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $165.38 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2, Proclaim |
| Sanofi-Aventis U.S. LLC | $158.89 | 2019-2021 | |
| Exact Sciences Corporation | $103.67 | 2023-2024 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $101.44 | 2023-2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $80.20 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.82 | 2022-2024 | Xifaxan |
| Ironwood Pharmaceuticals, INC | $43.18 | 2019-2020 | |
| Inari Medical, INC. | $33.14 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Stryker Corporation | $26.68 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Edwards Lifesciences Corporation | $25.16 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Inspire Medical Systems, INC. | $23.77 | 2024 | Inspire |
| E.R. Squibb & Sons, L.L.C. | $21.67 | 2023 | Eliquis |
| Phathom Pharmaceuticals, INC. | $19.84 | 2025 | Voquezna |
| Antares Pharma, INC. | $19.37 | 2022 | |
| Almatica Pharma LLC | $17.22 | 2021 | |
| Esperion Therapeutics, INC. | $17.15 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $14.08 | 2021 | |
| Eisai INC. | $13.71 | 2021 | |
| Shield Therapeutics INC | $13.45 | 2024 | |
| Allergan, INC. | $13.33 | 2020 | |
| Medicure Pharma INC. | $12.43 | 2021 | |
| Dynavax Technologies Corporation | $11.48 | 2023 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Preston Bishop listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.